Predicting drug susceptibility of non-small cell lung cancers based on genetic lesions.

doi:10.1172/JCI37127

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Predicting drug susceptibility of non-small cell lung cancers based on genetic lesions.

The Journal of clinical investigation - 1 Jun 2009

Sos Martin L, Michel Kathrin, Zander Thomas, Weiss Jonathan, Frommolt Peter, Peifer Martin, Li Danan, Ullrich Roland, Koker Mirjam, Fischer Florian, Shimamura Takeshi, Rauh Daniel, Mermel Craig, Fischer Stefanie, Stückrath Isabel, Heynck Stefanie, Beroukhim Rameen, Lin William, Winckler Wendy, Shah Kinjal, LaFramboise Thomas, Moriarty Whei F, Hanna Megan, Tolosi Laura, Rahnenführer Jörg, Verhaak Roel, Chiang Derek, Getz Gad, Hellmich Martin, Wolf Jürgen, Girard Luc, Peyton Michael, Weir Barbara A, Chen Tzu-Hsiu, Greulich Heidi, Barretina Jordi, Shapiro Geoffrey I, Garraway Levi A, Gazdar Adi F, Minna John D, Meyerson Matthew, Wong Kwok-Kin, Thomas Roman K

Abstract excerpt

Somatic genetic alterations in cancers have been linked with response to targeted therapeutics by creation of specific dependency on activated oncogenic signaling pathways. However, no tools currently exist to systematically connect such genetic lesions to therapeutic vulnerability. We have therefore developed a genomics approach to identify lesions associated with therapeutically relevant oncogene dependency....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Antineoplastic Agents

Share to Carcinoma, Non-Small-Cell Lung

Share to Drug Evaluation, Preclinical

Share to ErbB Receptors

Share to Gene Expression Profiling

Share to Magnetic Resonance Imaging

Share to Protein Structure, Tertiary

Share to Substrate Specificity

Source

Open in PubMed Open full text

Identifiers

PMID: 19451690
DOI: 10.1172/JCI37127
PMCID: PMC2689116

Genes

KRAS
SRC
ABL2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Predicting drug susceptibility of non-small cell lung cancers based on genetic lesions.PMID 19451690Read ↗

Systematically linking drug susceptibility to cancer genome aberrations.Semantic proximity Read ↗

Pharmacogenomics and targeted therapy of cancer: Focusing on non-small cell lung cancer.Semantic proximity Read ↗

A framework for identification of actionable cancer genome dependencies in small cell lung cancerSemantic proximity Read ↗

Individualized genetic network analysis reveals new therapeutic vulnerabilities in 6,700 cancer genomes.Semantic proximity Read ↗

Targeting mutations in cancer.Semantic proximity Read ↗

Pan-Cancer Pharmacogenomic Analysis of Patient-Derived Tumor Cells Using Clinically Relevant Drug Exposures.Semantic proximity Read ↗

Prospective Comprehensive Molecular Characterization of Lung Adenocarcinomas for Efficient Patient Matching to Approved and Emerging Therapies.Semantic proximity Read ↗

Large-Scale Profiling of Kinase Dependencies in Cancer Cell Lines.Semantic proximity Read ↗

Genetic determinants of lung cancer: Understanding the oncogenic potential of somatic missense mutations.Semantic proximity Read ↗

Comprehensive genetic testing identifies targetable genomic alterations in most patients with non-small cell lung cancer, specifically adenocarcinoma, single institute investigation.Semantic proximity Read ↗

Genetic predictors of MEK dependence in non-small cell lung cancer.Semantic proximity Read ↗

Methods and resources to access mutation-dependent effects on cancer drug treatment.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.